Novo Nordisk’s semaglutide drug, initially approved in 2017 as a diabetes treatment called Ozempic and later as an obese version called Wigovy in 2021, has made a significant impact. This drug is the newest analogue of glucagon-like peptide 1 (GLP1) and has garnered attention for its ability to survive in the blood longer than native GLP1, leading to improved efficiency in treating diabetes symptoms. This once-weekly injection has even shown a 15% weight loss in 2 years through its effect on the pancreas and brain. The drug’s popularity has soared, thanks to social media, with celebrities endorsing it and it going viral on platforms like TikTok.
Following the success of semaglutide, other drugs targeting multiple receptors have emerged. Eli Lilly’s tirzepatide, for example, targets both GLP1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering more effective results than semaglutide. Additionally, new compounds like letaltortide, targeting GLP1, GIP, and glucagon receptors, have shown promising results with almost a 25% weight loss in 48 weeks. AMGEN’s AMG133 takes a unique approach by blocking the GIP receptor with antibodies, resulting in a 15% weight loss in just 3 months when administered monthly.
These innovative approaches demonstrate the potential for customized treatments with increased efficacy and reduced side effects in combating obesity. While these drugs provide valuable treatment options, it’s essential to address the root cause of obesity through policy changes and poverty alleviation.
Source: www.sciencefocus.com
